文献速递前列腺增生与排尿功能障碍

对流热疗治疗良性前列腺增生所致下尿路症状:随机对照与前瞻性交叉研究的2年持久结果

Convective Thermal Therapy: Durable 2-Year Results of Randomized Controlled and Prospective Crossover Studies for Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia.
PubMed 文献 · J Urol · 2016-12-18

多中心随机对照试验纳入197例≥50岁、I-PSS≥13、最大尿流率≤15 ml/s、前列腺30-80 cc的男性,2:1随机接受Rezūm系统热疗或对照组。热疗组24个月症状评分较基线降低51%(p<0.0001),84%和74%受试者评分分别降低≥5分和≥8分;交叉后症状、尿流率和生活质量显著改善,无新发勃起功能障碍。

要点

  • 热疗组24个月I-PSS较基线降低51%(p<0.0001),84%降低≥5分、74%降低≥8分。
  • 交叉受试者热疗后症状、尿流率及生活质量较对照术后显著改善(p=0.024至<0.0001)。
  • 无新发勃起功能障碍报告,该微创门诊/日间手术适用于包括中叶在内的梗阻组织。

核心结论

  • 对流射频水蒸气热疗是一种微创门诊或日间手术,可提供早期有效的症状缓解并持续2年,且适用于中叶。

研究设计与样本

  • 多中心随机对照试验纳入197例≥50岁、I-PSS≥13、最大尿流率≤15 ml/s、前列腺30-80 cc的男性,2:1随机接受Rezūm系统热疗或对照组(硬性膀胱镜模拟主动治疗声音)。
  • 对照组3个月揭盲后可重新入组交叉研究,交叉试验报告1年结果。

主要发现

  • 热疗组3个月症状改善显著优于对照组,24个月I-PSS较基线降低51%(p<0.0001)。
  • 24个月时84%受试者I-PSS降低≥5分,74%降低≥8分。
  • 交叉受试者热疗后症状、尿流率和生活质量较对照术后显著改善(p=0.024至<0.0001)。
  • 无新发勃起功能障碍报告。

关键数值与推荐

  • 主要疗效终点为症状评分严重程度的变化。
  • 热疗组24个月I-PSS较基线降低51%(p<0.0001),84%受试者降低≥5分、74%降低≥8分。
  • 交叉受试者热疗后症状、尿流率及生活质量较对照术后改善(p=0.024至<0.0001)。

临床怎么用

  • 对流射频水蒸气热疗可作为适用于中叶的微创门诊或日间手术,提供早期有效且持续2年的症状缓解。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We report 2-year outcomes of a multicenter randomized controlled trial plus 1-year results of a crossover trial after treatment with convective radiofrequency water vapor thermal energy for lower urinary tract symptoms due to benign prostatic hyperplasia. MATERIALS AND METHODS: A total of 197 men at least 50 years old with I-PSS (International Prostate Symptom Score) 13 or greater, maximum flow rate 15 ml per second or less and prostate size 30 to 80 cc were randomized 2:1 to thermal therapy with the Rezūm® System or a control group. Rigid cystoscopy with simulated active treatment sounds served as the control procedure. After unblinding at 3 months control subjects could requalify for crossover study. Convectively delivered radiofrequency thermal energy was delivered into obstructive prostate tissue, including the median lobe as needed. The primary efficacy end point was a change in severity of symptom scores. RESULTS: Convective radiofrequency thermal therapy improved urinary symptoms significantly over controls at 3 months and provided a sustained 51% reduction from baseline at 24 months (p <0.0001). This produced a 5 and 8-point or greater score decrease in 84% and 74% of subjects, respectively, at 24 months. Crossover subject symptoms, flow rate and quality of life measures were markedly improved after thermal therapy compared to after the control procedure (p = 0.024 to <0.0001). No de novo erectile dysfunction was reported. CONCLUSIONS: Convective radiofrequency water vapor thermal therapy is a minimally invasive office or outpatient procedure that provides early effective symptom relief that remains durable for 2 years and is applicable to the median lobe.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Roehrborn CG, Gange SN, Gittelman MC, et al. Convective Thermal Therapy: Durable 2-Year Results of Randomized Controlled and Prospective Crossover Studies for Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia. J Urol. 2016. PMID: 27993667. doi:10.1016/j.juro.2016.12.045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。